Survival Among Patients With Pancreatic Cancer Depending on Surgical Resection Rate

NCT ID: NCT04802993

Last Updated: 2021-03-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

5123 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-01-01

Study Completion Date

2020-10-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary aim of this population-based study is to investigate how a high resection rate of pancreaticoduodenectomy affects overall survival among patients aged ≥70 years with pancreatic ductal adenocarcinoma. The secondary aim is to determine if a high resection rate of pancreaticoduodenectomy increases perioperative morbidity.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Ductal Adenocarcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All patients with pancreatic ductal adenocarcinoma aged 70 years and older

All patients in the registry aged 70 years and older with right-sided pancreatic ductal adenocarcinoma

Resection rates

Intervention Type OTHER

All groups are divided into one high- and one low resection rate group depending on percentage of patients with pancreatic ductal adenocarcinoma resected per county and year (first three groups) and resection rate of pancreaticoduodenectomy per 100 000 inhabitants per county (last three groups)

All patients with pancreatic ductal adenocarcinoma aged 70-79 years

All patients in the registry aged 70-79 years with right-sided pancreatic ductal adenocarcinoma

Resection rates

Intervention Type OTHER

All groups are divided into one high- and one low resection rate group depending on percentage of patients with pancreatic ductal adenocarcinoma resected per county and year (first three groups) and resection rate of pancreaticoduodenectomy per 100 000 inhabitants per county (last three groups)

All patients with pancreatic ductal adenocarcinoma aged 80 years and older

All patients in the registry aged 80 years and older with right-sided pancreatic ductal adenocarcinoma

Resection rates

Intervention Type OTHER

All groups are divided into one high- and one low resection rate group depending on percentage of patients with pancreatic ductal adenocarcinoma resected per county and year (first three groups) and resection rate of pancreaticoduodenectomy per 100 000 inhabitants per county (last three groups)

All patients resected with pancreaticoduodenectomy, all ages

All patients in the registry resected with pancreaticoduodenectomy during the study period

Resection rates

Intervention Type OTHER

All groups are divided into one high- and one low resection rate group depending on percentage of patients with pancreatic ductal adenocarcinoma resected per county and year (first three groups) and resection rate of pancreaticoduodenectomy per 100 000 inhabitants per county (last three groups)

All patients resected with pancreaticoduodenectomy, aged 70-79 years

All patients in the registry resected with pancreaticoduodenectomy during the study period, aged 70-79 years

Resection rates

Intervention Type OTHER

All groups are divided into one high- and one low resection rate group depending on percentage of patients with pancreatic ductal adenocarcinoma resected per county and year (first three groups) and resection rate of pancreaticoduodenectomy per 100 000 inhabitants per county (last three groups)

All patients resected with pancreaticoduodenectomy, aged 80 years and older

All patients in the registry resected with pancreaticoduodenectomy during the study period, aged 80 years and older

Resection rates

Intervention Type OTHER

All groups are divided into one high- and one low resection rate group depending on percentage of patients with pancreatic ductal adenocarcinoma resected per county and year (first three groups) and resection rate of pancreaticoduodenectomy per 100 000 inhabitants per county (last three groups)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Resection rates

All groups are divided into one high- and one low resection rate group depending on percentage of patients with pancreatic ductal adenocarcinoma resected per county and year (first three groups) and resection rate of pancreaticoduodenectomy per 100 000 inhabitants per county (last three groups)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed between 1 January 2010 and 31 December 2018
* Registered in the Swedish National Registry for tumours in the pancreatic and periampullary region
* Either a diagnosis of pancreatic ductal adenocarcinoma of the pancreatic head or having been resected with pancreaticoduodenectomy

Exclusion Criteria

* None
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Linkoeping University

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Bergthor Björnsson

Ass. Professor, senior consultant

Responsibility Role PRINCIPAL_INVESTIGATOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2017/151-31

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.